$KNTK

ISQ Global Fund II GP LLC (Wahba Sadek, Bhandari Gautam) sold $798K of KNTK (indirect holdings)

ISQ Global Fund II GP LLC sold 14,483 indirectly-held shares of Kinetik Holdings Inc. (KNTK) at an average of $55.08 ($55.06–$55.15, $0.80M total) across 3 trades over 2026-09-14 to 2026-09-16. Filed jointly with I Squared Capital, LLC (10% owner), ISQ Holdings, LLC (10% owner), Wahba Sadek (10% owner) and Bhandari Gautam (10% owner).

Original reporting
SEC EDGAR · ISQ Global Fund II GP LLC, I Squared Capital, LLC, ISQ Holdings, LLC, Wahba Sadek, Bhandari Gautam
Published Sep 17, 2026, 12:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 1:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KNTK
Bearish
medium confidence
Mentioned
$KNTK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KNTKBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, which may influence short‑term trading decisions.

02

Market read

Primary disclosure of an insider transaction; modest relevance for traders monitoring KNTK.

03

What to watch

The sale was executed via open market trades over three days, possibly to avoid market impact.

Relevance 5/10Novelty 4/10Timing: filed 2026-09-16

Background

Kinetik Holdings Inc. is a biotech company developing RNA‑based therapeutics. The filing discloses a recent insider sale by a 10% owner.

Company-level read

Ticker impact

$KNTKBearishMedium confidence
Context

Form 4 shows ISQ Global Fund II GP LLC sold ~800K of KNTK shares at $55.08 average, reducing its stake.

Expected impact

Potential modest downside pressure over next few days.

Evidence & confidence

Sale size is modest relative to float, but insider ownership is notable (10% owner).

Market effects

Minimal impact on biotech sector; insider activity is company‑specific.

No broader regional effect.

Limited to investors tracking KNTK.

Counterpoint

Insider sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Kinetik Holdings Inc.

    Biotech firm (ticker KNTK) subject of the Form 4 filing.

  • ISQ Global Fund II GP LLC

    10% owner selling shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KNTKMedAI 8/10

Why is Kinetik Holdings stock surging today?

Kinetik Holdings' stock rose 5.2% in after-hours trading after Bloomberg reported the company is exploring strategic alternatives, including a potential sale. The company posted record Q2 2026 results with revenue up 36% YoY and net income more than doubled. Kinetik's management had raised its full-year 2026 guidance. U.S. equities broadly sold off during regular trading hours, with the S&P 500, Dow Jones, and Nasdaq all declining.

Med

Kinetik stock jumps 5% on potential sale exploration report

Kinetik Holdings Inc. (KNT) shares rose 5% in after-hours trading after reports it is exploring strategic options, including a potential sale. The company, backed by Blackstone Inc. (BX), has a market value of $8.9B. No final decision has been made. Kinetik closed regular trading at $54.55, down 0.8% but up 30% over the past year.

$KNTKMed

Kinetik Q2 Earnings Call Highlights

Kinetik (NYSE:KNTK) Q2 earnings call said Waha pricing normalization and faster curtailment return, higher WTI and liquids assumptions, and system operating improvements supported a revised outlook. It raised 2026 capex to about $560M, expects Q3 Adjusted EBITDA $260M-$270M and Q4 $270M-$280M, and lifted 2026 volume growth to mid- to high-single digits.